Laurie Sehn, MD, on Brentuximab Vedotin in Diffuse Large B-Cell Lymphoma With Undetectable CD30
2014 ASH Annual MeetingLaurie Sehn, MD, of the BC Cancer Agency, on abstract 629, “Brentuximab Vedotin Monotherapy in Diffuse Large B-Cell Lymphoma Patients With Undetectable CD30: Preliminary Results From a Phase II Study.”